Last edition
News about "Novo Nordisk Cuts Annual Outlook Again as Wegovy S"
Novo Nordisk Cuts Annual Outlook Again as Wegovy Supply Woes Persist
Shares of Novo Nordisk fell sharply after the company once again lowered its annual forecast, citing ongoing supply challenges for its blockbuster obesity drug Wegovy. Despite a 25% jump in second-quarter sales and a 28% rise in net profit, the Danish drugmaker scaled back expectations for full-year operating profit and sales growth.
Novo Nordisk Cuts Annual Outlook Again As Wegovy S | 30/07/2025 | By Darshana | 129
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy